Browsing by Author Galle, Peter R.
Showing results 1 to 4 of 4
| Issue Date | Title | Author(s) |
|---|---|---|
| 13-Nov-2020 | Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2 | Kudo, Masatoshi; Galle, Peter R.; Brandi, Giovanni; Kang, Yoon Koo; Yen, Chia Jui; Finn, Richard S.; Llovet i Bayer, Josep Maria; Assenat, Eric; Merle, Philippe; Chan, Stephen L.; Palmer, Daniel H.; Ikeda, Masafumi; Yamashita, Tatsuya; Vogel, Arndt; Huang, Yi Hsiang; Abada, Paolo; Yoshikawa, Reigetsu; Shinozaki, Kenta; Wang, Chunxiao; Widau, Ryan C.; Zhu, Andrew X. |
| 14-Nov-2020 | Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab | Reig, María; Galle, Peter R.; Kudo, Masatoshi; Finn, Richard; Llovet i Bayer, Josep Maria; Metti, Andrea L.; Schelman, William R.; Liang, Kun; Wang, Chunxiao; Widau, Ryan C.; Abada, Paolo; Zhu, Andrew X. |
| Aug-2020 | Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2 | Kudo, Masatoshi; Galle, Peter R.; Llovet i Bayer, Josep Maria; Finn, Richard S.; Vogel, Arndt; Motomura, Kenta; Assenat, Eric; Merle, Philippe; Brandi, Giovanni; Daniele, Bruno; Okusaka, Takuji; Tomášek, Jiří; Borg, Christophe; Dadduzio, Vincenzo; Morimoto, Manabu; Pracht, Marc; Jen, Min-Hua; Widau, Ryan C.; Shinozaki, Kenta; Yoshikawa, Reigetsu; Zhu, Andrew X. |
| 1-Jan-2020 | Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials | Zhu, Andrew X.; Nipp, Ryan D.; Finn, Richard S.; Galle, Peter R.; Llovet i Bayer, Josep Maria; Blanc, Jean Frederic; Okusaka, Takuji; Chau, Ian; Cella, David; Girvan, Alicia; Gable, Jonathon; Bowman, Lee; Wang, Chunxiao; Hsu, Yanzhi; Abada, Paolo; Kudo, Masatoshi |